Olema Pharmaceuticals (OLMA) late Tuesday reported Q4 net loss of $0.51 per diluted share, compared with $0.49 loss a year earlier.
The four analysts polled by FactSet, on average, expected a loss of $0.65.
The biopharmaceutical company recorded no revenue during the quarter ended Dec. 31, as expected.
Olema finished 2024 with around $434.1 million in cash and equivalents, up from $261.8 million at the end of 2023.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。